NCT04556253进行中（未招募）2 期
A Multicenter, Open-Label, Phase II Study of Anti-PD-1/CTLA-4 Bispecific Antibody AK104 in the Perioperative Treatment of Locally Advanced Microsatellite Instability/Mismatch Repair Protein-Deficient Gastric and Colorectal Cancers
Peking University1 个研究点 分布在 1 个国家目标入组 47 人开始时间: 2024年2月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 47
- 试验地点
- 1
- 主要终点
- The rate of pathologic complete response(pCR%)
研究概览
简要总结
This is a single-arm, multicenter phase II clinical study. The aim is to evaluate the safety, tolerability, and anti-tumor activities of AK104(a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced gastric adenocarcinoma and colorectal cancer during the perioperative period.Eligible patients will receive AK104 for three cycles before surgery and at most 6 months after surgery. The primary endpoint is the pathological complete response rate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written and signed informed consent.
- •Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or
- •The estimated life expectancy of ≥3 months.
- •Confirmed MSI-H/dMMR status by the central laboratory.
- •For cohort 1, histologically or cytologically documented locally advanced gastric carcinoma(cT3-T4a, Nx, M0). For cohort 2, histologically or cytologically documented locally advanced colorectal cancer(cT2-T4a, Nx, M0).
- •Haven't received any chemotherapy or radiotherapy.
- •Adequate organ function.
- •All female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the Investigator, during and for 120 days after the last dose of study treatment.
排除标准
- •Is currently participating in a study of an investigational agent or using an investigational device;
- •Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy within 2 years prior to the first dose of study treatment;
- •Has undergone major surgery within 30 days of Study Day 1;
- •Has a known additional malignancy that is progressing or requires systemic treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
- •Has known active central nervous system (CNS) metastases;
- •Has carcinomatous meningitis;
- •Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment NOTE: Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study;
- •Has an active infection requiring systemic therapy;
- •Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected);
- •History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery within 12 months prior to day 1 of study treatment;
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of this subject to participate, in the opinion of the treating investigator;
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study;
- •Has received a live virus vaccine within 30 days of the planned first dose of study therapy;
- •Is pregnant, breastfeeding, or expecting to conceive or father a child within the projected duration of the study including 120 days following the last dose of study treatment;
- •Has any concurrent medical condition that, in the opinion of the Investigator, would complicate or compromise compliance with the study or the well-being of the subject.
研究组 & 干预措施
treatment arm
Experimental
Subjects will receive AK104 by intravenous administration.
干预措施: AK104 (Drug)
结局指标
主要结局
The rate of pathologic complete response(pCR%)
时间窗: through study completion, an average of 1 year
The rate of pathologic complete response evaluated by investigator
次要结局
未报告次要终点
研究者
Jiafu Ji
Head of Beijing Cancer Hospital
Peking University
研究点 (1)
Loading locations...
相似试验
终止
1 期
A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell LymphomaPeripheral T-cell LymphomaNCT04444141Akeso6
尚未招募
2 期
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCCUnresectable Esophageal Squamous Cell CarcinomaLocally Advanced Esophageal Squamous Cell CarcinomaMetastatic Esophageal Squamous Cell CarcinomaNCT05522894Chinese Academy of Medical Sciences80
已完成
1 期
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid TumorsAdvanced Solid TumorsMelanomaNCT04172454Akeso68
招募中
2 期
AK104 for Recurrent or Metastatic Vulvar CancerVulvar CancerNCT05932212Akeso20
招募中
2 期
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung CancerNon-small Cell Lung CancerNCT05377658Henan Cancer Hospital43